# Inherited Retinal Disease Gene Therapy Sector

Canonical URL: https://biopharmsignal.com/sector/inherited-retinal-disease-gene-therapy

Inherited Retinal Disease Gene Therapy is a company sector tag on BioPharmSignal. This page groups public biotech and healthcare companies associated with Inherited Retinal Disease Gene Therapy, making it easier to scan related businesses, compare peers, and follow companies exposed to the same modality, disease area, or development theme.

Companies currently grouped under Inherited Retinal Disease Gene Therapy: 3

## Recent Sector News

- 2026-09-01 11:02 EST — OCGN — [Ocugen Announces First Patient Dosed in Phase 3 Registrational Trial of OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration](https://biopharmsignal.com/news/OCGN/ocugen-announces-first-patient-dosed-in-phase-3-registrational-trial-of-ocu410-m-5728a6d6) — Source: Ocugen
- 2026-08-25 11:02 EST — OCGN — [Ocugen to Participate in Upcoming September Investor and Industry Conferences](https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-september-investor-and-industry-conferences-16cf3119) — Source: Ocugen
- 2026-08-13 12:00 EST — MGTX — [MeiraGTx Reports Second Quarter 2026 Financial and Operational Results](https://biopharmsignal.com/news/MGTX/meiragtx-reports-second-quarter-2026-financial-and-operational-results-7f83916b) — Source: MeiraGTx
- 2026-08-06 20:30 EST — MGTX — [MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-3ee9d0a1) — Source: MeiraGTx
- 2026-08-06 11:02 EST — OCGN — [Ocugen Provides Business Update with Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/OCGN/ocugen-provides-business-update-with-second-quarter-2026-financial-results-5feb3ea6) — Source: Ocugen
- 2026-07-31 11:02 EST — OCGN — [Ocugen to Participate in Upcoming August Investor Conferences](https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-august-investor-conferences-2ecb8549) — Source: Ocugen
- 2026-07-29 11:01 EST — OCGN — [Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration](https://biopharmsignal.com/news/OCGN/ocugen-announces-that-the-u-s-food-and-drug-administration-has-granted-ocu410-re-ce6aa687) — Source: Ocugen
- 2026-07-28 20:01 EST — OCGN — [Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/OCGN/ocugen-to-host-conference-call-on-thursday-august-6-at-8-30-a-m-et-to-discuss-bu-9cbdb920) — Source: Ocugen
- 2026-07-13 11:02 EST — OCGN — [Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa](https://biopharmsignal.com/news/OCGN/ocugen-inc-announces-binding-term-sheet-with-roots-pharmaceutical-to-license-ocu-2ac6b744) — Source: Ocugen
- 2026-07-07 11:30 EST — MGTX — [MeiraGTx Announces $400 million Strategic Investment by Oberland Capital to Support Development and Commercialization of AAV2-hAQP1 and Botaretigene Sparoparvovec (bota-vec)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-400-million-strategic-investment-by-oberland-capital-to-suppo-b21561a1) — Source: MeiraGTx
- 2026-07-01 11:00 EST — OCGN — [Ocugen to Participate in Upcoming July Industry Conferences](https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-july-industry-conferences-c2e70176) — Source: Ocugen
- 2026-06-02 11:03 EST — OCGN — [Ocugen to Participate in Upcoming June Investor and Industry Conferences](https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-june-investor-and-industry-conferences-694d1d48) — Source: Ocugen
- 2026-05-14 20:30 EST — MGTX — [MeiraGTx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/MGTX/meiragtx-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4) — Source: MeiraGTx
- 2026-05-14 20:30 EST — OCGN — [Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes](https://biopharmsignal.com/news/OCGN/ocugen-inc-announces-closing-for-130-0-million-of-6-75-convertible-senior-notes-c2674be1) — Source: Ocugen
- 2026-05-14 12:00 EST — MGTX — [MeiraGTx Reports First Quarter 2026 Financial and Operational Results](https://biopharmsignal.com/news/MGTX/meiragtx-reports-first-quarter-2026-financial-and-operational-results) — Source: MeiraGTx
- 2026-05-13 11:02 EST — OCGN — [Ocugen to Participate in Upcoming May Scientific and Investor Conferences](https://biopharmsignal.com/news/OCGN/ocugen-to-participate-in-upcoming-may-scientific-and-investor-conferences-19c82528) — Source: Ocugen
- 2026-05-05 12:32 EST — OCGN — [Ocugen Provides Business Update with First Quarter 2026 Financial Results](https://biopharmsignal.com/news/OCGN/ocugen-provides-business-update-with-first-quarter-2026-financial-results-655a18c1) — Source: Ocugen
- 2026-05-05 12:12 EST — OCGN — [Ocugen, Inc. Announces Pricing of $115 Million of 6.75% Convertible Senior Notes](https://biopharmsignal.com/news/OCGN/ocugen-inc-announces-pricing-of-115-million-of-6-75-convertible-senior-notes-2f1e5939) — Source: Ocugen
- 2026-05-04 20:01 EST — OCGN — [Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes](https://biopharmsignal.com/news/OCGN/ocugen-announces-private-offering-of-115-million-of-convertible-senior-notes-7be33294) — Source: Ocugen
- 2026-04-29 11:02 EST — OCGN — [Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results](https://biopharmsignal.com/news/OCGN/ocugen-to-host-conference-call-on-tuesday-may-5-at-8-30-a-m-et-to-discuss-busine-6b6c1f44) — Source: Ocugen

## Companies

- [ADVM](https://biopharmsignal.com/company/ADVM) — Adverum Biotechnologies
- [MGTX](https://biopharmsignal.com/company/MGTX) — MeiraGTx
- [OCGN](https://biopharmsignal.com/company/OCGN) — Ocugen